Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve). • MRK shares are experiencing downward pressure. Check out the latest moves here.The success criterion for the primary efficacy hypothesis, as measured by the percentage of participants with HIV-1 RNA levels <5 ...